INTRAHEPATIC CHOLANGIOCARCINOMA

This study tests whether a liver transplant after a combination of internal radiation therapy (SIRT) and chemotherapy can help people with a certain type of bile duct cancer that cannot be removed by surgery but has not spread. The goal is to see if this approach improves surviva…

This study tests whether adding a liver-directed chemotherapy (HAI FUDR/Dexamethasone) to standard chemo (GemOx) can delay cancer growth in people with bile duct cancer that can't be surgically removed. About 164 adults with cancer confined to the liver will be randomly assigned …

This study tests a new combination of drugs as the first treatment for people with advanced intrahepatic cholangiocarcinoma, a type of liver cancer that cannot be removed by surgery. About 35 participants will receive an oral drug called chidamide along with standard chemotherapy…

This study is for people with a type of bile duct cancer that cannot be removed by surgery and has not spread. Participants will receive chemotherapy first, and if the cancer stays stable or shrinks for at least 6 months, they may get a liver transplant. The goal is to see if thi…

This study tests a new drug, ALE.P03, that delivers a cancer-killing agent directly to tumor cells with a specific marker (CLDN1). It is for adults with advanced or metastatic cancers of the cervix, lung, colon, bile duct, or bladder that have not responded to standard treatments…

This study tests a combination of two drugs (pemigatinib and durvalumab) in adults with advanced bile duct cancer that has a specific change in the FGFR-2 gene. The goal is to see if the combination shrinks tumors or slows cancer growth. Participants take one pill daily for two w…

This study tests a new way to give radiation for liver cancer in just one session, using real-time MRI to guide the beam and adjust the plan on the spot. It aims to improve survival and reduce side effects. About 62 adults with liver cancer or liver metastases will take part.

This study is for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be removed by surgery. It compares two treatments delivered directly to the liver's blood supply—HAI-FUDR/DEX and SIRT—both given alongside standard chemotherapy. The goal is to shr…

This study looks at whether a chemotherapy pump placed in the liver's main blood vessel is safe and practical for people with colorectal cancer or bile duct cancer that has spread to the liver. About 80 participants will get the pump surgically implanted and then choose to have t…

This study aims to develop a blood test that can accurately distinguish between two common types of liver cancer—hepatocellular carcinoma and cholangiocarcinoma—before surgery. Researchers will analyze tiny particles called exosomes in the blood using machine learning. The goal i…

This early-stage trial is testing whether giving chemotherapy as a fine mist directly into the abdomen (PIPAC) can reduce side effects for people with biliary tract cancer that has spread to the lining of the belly. About 12 participants will receive this mist along with standard…

This study tests whether people with liver cancer can receive a treatment that goes into the liver's blood vessels (called TACE or TARE) as an outpatient instead of staying overnight in the hospital. About 206 adults with primary liver cancer will be randomly assigned to either o…